Sarepta (SRPT) +11.5% to $12.02 after a positive weekend article in Barrons about the company's Eteplirsen treatment for Duchenne muscular dystrophy, which could receive expedited approval from the FDA if its Phase IIb trials are as strong as earlier studies. One analyst has a price target of $16 and reckons peak sales could hit $600M; however, writing on The Street, Nathan Sadeghi-Nejad remains cautious
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
